Cambrex wins Green Chemistry Award
Analysis based on 17 articles · First reported Jul 06, 2026 · Last updated Jul 08, 2026
The award and sustainability achievements enhance Cambrex's reputation as an innovative and environmentally responsible CDMO, potentially attracting more clients. The cost reductions in obicetrapib manufacturing could benefit NewAmsterdam Pharma's drug development.
Cambrex, a global CDMO, announced that its subsidiary Snapdragon Chemistry, together with NewAmsterdam Pharma, received the American Chemical Society's 2026 Green Chemistry Challenge Award for developing a sustainable organocatalytic process to manufacture obicetrapib, a dyslipidemia therapy. The process improved yield, reduced waste by 80%, cut cycle time by 70%, and lowered costs by 50%. Additionally, Cambrex's Milan facility earned EcoVadis Gold rating, and Q1 Scientific partnered with Flogas for renewable electricity.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard